Skip to main content
Top
Published in: Conflict and Health 1/2017

Open Access 01-12-2017 | Research

Low levels of viral suppression among refugees and host nationals accessing antiretroviral therapy in a Kenyan refugee camp

Authors: Joshua B. Mendelsohn, Paul Spiegel, Alison Grant, Sathyanarayanan Doraiswamy, Marian Schilperoord, Natasha Larke, John Wagacha Burton, Jully A. Okonji, Clement Zeh, Bosco Muhindo, Ibrahim M. Mohammed, Irene N. Mukui, Njogu Patterson, Egbert Sondorp, David A. Ross

Published in: Conflict and Health | Issue 1/2017

Login to get access

Abstract

Background

Refugees and host nationals who accessed antiretroviral therapy (ART) in a remote refugee camp in Kakuma, Kenya (2011–2013) were compared on outcome measures that included viral suppression and adherence to ART.

Methods

This study used a repeated cross-sectional design (Round One and Round Two). All adults (≥18 years) receiving care from the refugee camp clinic and taking antiretroviral therapy (ART) for ≥30 days were invited to participate. Adherence was measured by self-report and monthly pharmacy refills. Whole blood was measured on dried blood spots. HIV-1 RNA was quantified and treatment failures were submitted for drug resistance testing. A remedial intervention was implemented in response to baseline testing. The primary outcome was viral load <5000 copies/mL. The two study rounds took place in 2011-2013.

Results

Among eligible adults, 86% (73/85) of refugees and 84% (86/102) of Kenyan host nationals participated in the Round One survey; 60% (44/73) and 58% (50/86) of Round One participants were recruited for Round Two follow-up viral load testing. In Round One, refugees were older than host nationals (median age 36 years, interquartile range, IQR 31, 41 vs 32 years, IQR 27, 38); the groups had similar time on ART (median 147 weeks, IQR 38, 64 vs 139 weeks, IQR 39, 225). There was weak evidence for a difference in the proportion of refugees and host nationals who were virologically suppressed (<5000 copies/mL) after 25 weeks on ART (58% vs 43%, p = 0.10) and no difference in the proportions suppressed at Round Two (74% vs 70%, p = 0.66). Mean adherence within each group in Round One was similar. Refugee status was not associated with viral suppression in multivariable analysis (adjusted odds ratio: 1.69, 95% CI 0.79, 3.57; p = 0.17). Among those not suppressed at either timepoint, 69% (9/13) exhibited resistance mutations.

Conclusions

Virologic outcomes among refugees and host nationals were similar but unacceptably low. Slight improvements were observed after a remedial intervention. Virologic monitoring was important for identifying an underperforming ART program in a remote facility that serves refugees alongside host nationals. This work highlights the importance of careful laboratory monitoring of vulnerable populations accessing ART in remote settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Centre for Research on Epidemiology of Disasters. People affected by conflict 2013: Humanitarian needs in numbers. Brussels: Centre for Research on Epidemiology of Disasters; 2013. Centre for Research on Epidemiology of Disasters. People affected by conflict 2013: Humanitarian needs in numbers. Brussels: Centre for Research on Epidemiology of Disasters; 2013.
2.
go back to reference UNHCR. Statistical Yearbook 2013, 13th edition. Geneva: UNHCR; 2014. UNHCR. Statistical Yearbook 2013, 13th edition. Geneva: UNHCR; 2014.
3.
go back to reference United Nations General Assembly. Convention Relating to the Status of Refugees, 28 July 1951, United Nations, Treaty Series, vol. 189, p. 137. Entry into force 22 April 1954, in accordance with article 43. United Nations General Assembly. Convention Relating to the Status of Refugees, 28 July 1951, United Nations, Treaty Series, vol. 189, p. 137. Entry into force 22 April 1954, in accordance with article 43.
4.
go back to reference Mendelsohn JB, Schilperoord M, Spiegel P, Ross DA. Adherence to antiretroviral therapy and treatment outcomes in conflict-affected and forcibly displaced populations: a systematic review. Confl Health. 2012;6(9):epub. Mendelsohn JB, Schilperoord M, Spiegel P, Ross DA. Adherence to antiretroviral therapy and treatment outcomes in conflict-affected and forcibly displaced populations: a systematic review. Confl Health. 2012;6(9):epub.
5.
go back to reference Griffiths K, Ford N. Provision of antiretroviral care to displaced populations in humanitarian settings: a systematic review. Med Confl Surviv. 2013;29(3):198–215.CrossRefPubMed Griffiths K, Ford N. Provision of antiretroviral care to displaced populations in humanitarian settings: a systematic review. Med Confl Surviv. 2013;29(3):198–215.CrossRefPubMed
6.
go back to reference Mendelsohn JB, Schilperoord M, Spiegel P, Balasundaram S, Radhakrishnan A, Lee CK, et al. Is forced migration a barrier to treatment success? Similar HIV treatment outcomes among refugees and a surrounding host community in Kuala Lumpur, Malaysia. AIDS Behav. 2014;18(2):323–34.CrossRefPubMed Mendelsohn JB, Schilperoord M, Spiegel P, Balasundaram S, Radhakrishnan A, Lee CK, et al. Is forced migration a barrier to treatment success? Similar HIV treatment outcomes among refugees and a surrounding host community in Kuala Lumpur, Malaysia. AIDS Behav. 2014;18(2):323–34.CrossRefPubMed
7.
go back to reference Spiegel PB, Checchi F, Colombo S, Paik E. Health-care needs of people affected by conflict: future trends and changing frameworks. Lancet. 2010;375(9711):341–5.CrossRefPubMed Spiegel PB, Checchi F, Colombo S, Paik E. Health-care needs of people affected by conflict: future trends and changing frameworks. Lancet. 2010;375(9711):341–5.CrossRefPubMed
8.
go back to reference UNHCR, Southern African HIV Clinicians Society. Clinical guidelines for antiretroviral therapy management for displaced populations. Geneva: UNHCR; 2007. UNHCR, Southern African HIV Clinicians Society. Clinical guidelines for antiretroviral therapy management for displaced populations. Geneva: UNHCR; 2007.
10.
go back to reference Finitsis DJ, Pellowski JA, Huedo-Medina TB, Fox MC, Kalichman SC. Visual analogue scale (VAS) measurement of antiretroviral adherence in people living with HIV (PLWH): a meta-analysis. J Behav Med. 2016;39(6):1043–55.CrossRefPubMed Finitsis DJ, Pellowski JA, Huedo-Medina TB, Fox MC, Kalichman SC. Visual analogue scale (VAS) measurement of antiretroviral adherence in people living with HIV (PLWH): a meta-analysis. J Behav Med. 2016;39(6):1043–55.CrossRefPubMed
11.
go back to reference Sangeda RZ, Mosha F, Prosperi M, Aboud S, Vercauteren J, Camacho RJ, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14:1035.CrossRefPubMedPubMedCentral Sangeda RZ, Mosha F, Prosperi M, Aboud S, Vercauteren J, Camacho RJ, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14:1035.CrossRefPubMedPubMedCentral
12.
go back to reference World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.
13.
go back to reference Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol. 2012;50(6):1936–42.CrossRefPubMedPubMedCentral Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol. 2012;50(6):1936–42.CrossRefPubMedPubMedCentral
15.
go back to reference Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):6–14.PubMed Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):6–14.PubMed
16.
17.
18.
go back to reference Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infec Dis. 2009;9:81.CrossRef Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infec Dis. 2009;9:81.CrossRef
19.
go back to reference Arnedo M, Alonso E, Eisenberg N, Ibanez L, Ferreyra C, Jaen A, et al. Monitoring HIV viral load in resource limited settings: still a matter of debate? PloS one. 2012;7(12):e47391.CrossRefPubMedPubMedCentral Arnedo M, Alonso E, Eisenberg N, Ibanez L, Ferreyra C, Jaen A, et al. Monitoring HIV viral load in resource limited settings: still a matter of debate? PloS one. 2012;7(12):e47391.CrossRefPubMedPubMedCentral
20.
go back to reference McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013;91(5):377–85E.CrossRefPubMedPubMedCentral McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013;91(5):377–85E.CrossRefPubMedPubMedCentral
21.
go back to reference McCarthy K, Chersich MF, Vearey J, Meyer-Rath G, Jaffer A, Simpwalo S, et al. Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa. Int J STD AIDS. 2009;20:858–62.CrossRefPubMed McCarthy K, Chersich MF, Vearey J, Meyer-Rath G, Jaffer A, Simpwalo S, et al. Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa. Int J STD AIDS. 2009;20:858–62.CrossRefPubMed
22.
go back to reference Kiboneka A, Nyatia RJ, Nabiryo C, Anema A, Cooper CL, Fernandes KA, et al. Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ. 2009;338:b201.CrossRefPubMedPubMedCentral Kiboneka A, Nyatia RJ, Nabiryo C, Anema A, Cooper CL, Fernandes KA, et al. Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ. 2009;338:b201.CrossRefPubMedPubMedCentral
23.
go back to reference O'Brien DP, Venis S, Greig J, Shanks L, Ellman T, Sabapathy K, et al. Provision of antiretroviral treatment in conflict settings: the experience of Médecins Sans Frontières. Confl Health. 2010;4:12.CrossRefPubMedPubMedCentral O'Brien DP, Venis S, Greig J, Shanks L, Ellman T, Sabapathy K, et al. Provision of antiretroviral treatment in conflict settings: the experience of Médecins Sans Frontières. Confl Health. 2010;4:12.CrossRefPubMedPubMedCentral
24.
go back to reference Culbert H, Tu D, O'Brien DP, Ellman T, Mills C, Ford N, et al. HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med. 2007;4(5):e129.CrossRefPubMedPubMedCentral Culbert H, Tu D, O'Brien DP, Ellman T, Mills C, Ford N, et al. HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med. 2007;4(5):e129.CrossRefPubMedPubMedCentral
25.
go back to reference Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155–66.CrossRefPubMed Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155–66.CrossRefPubMed
26.
go back to reference Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.CrossRefPubMedPubMedCentral Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.CrossRefPubMedPubMedCentral
27.
go back to reference Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, et al. The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PloS one. 2010;5(3):e9538.CrossRefPubMedPubMedCentral Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, et al. The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PloS one. 2010;5(3):e9538.CrossRefPubMedPubMedCentral
28.
go back to reference Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380(9849):1250–8.CrossRefPubMedPubMedCentral Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380(9849):1250–8.CrossRefPubMedPubMedCentral
29.
go back to reference Hassan AS, Mwaringa SM, Obonyo CA, Nabwera HM, Sanders EJ. Rinke de Wit TF, et al. Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya. AIDS Res Hum Retrovir. 2013;29(1):129–35.CrossRefPubMedPubMedCentral Hassan AS, Mwaringa SM, Obonyo CA, Nabwera HM, Sanders EJ. Rinke de Wit TF, et al. Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya. AIDS Res Hum Retrovir. 2013;29(1):129–35.CrossRefPubMedPubMedCentral
30.
go back to reference Sigaloff KC, Mandaliya K, Hamers RL, Otieno F, Jao IM, Lyagoba F, et al. Short communication: high prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retrovir. 2012;28(9):1033–7.PubMed Sigaloff KC, Mandaliya K, Hamers RL, Otieno F, Jao IM, Lyagoba F, et al. Short communication: high prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retrovir. 2012;28(9):1033–7.PubMed
31.
go back to reference Sigaloff KC, Hamers RL, Menke J, Labib M, Siwale M, Ive P, et al. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012;54 Suppl 4:S294–9.CrossRefPubMed Sigaloff KC, Hamers RL, Menke J, Labib M, Siwale M, Ive P, et al. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012;54 Suppl 4:S294–9.CrossRefPubMed
32.
go back to reference Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375(9709):123–31.CrossRefPubMed Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375(9709):123–31.CrossRefPubMed
33.
go back to reference Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr (1999). 2005;38(3):289–95. Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr (1999). 2005;38(3):289–95.
34.
go back to reference Mendelsohn JB, Rhodes T, Spiegel P, Schilperoord M, Burton JW, Balasundaram S, et al. Bounded agency in humanitarian settings: a qualitative study of adherence to antiretroviral therapy among refugees situated in Kenya and Malaysia. Soc Sci Med. 2014;120:387–95.CrossRefPubMed Mendelsohn JB, Rhodes T, Spiegel P, Schilperoord M, Burton JW, Balasundaram S, et al. Bounded agency in humanitarian settings: a qualitative study of adherence to antiretroviral therapy among refugees situated in Kenya and Malaysia. Soc Sci Med. 2014;120:387–95.CrossRefPubMed
35.
go back to reference Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med. 2009;24(1):14–20.CrossRefPubMed Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med. 2009;24(1):14–20.CrossRefPubMed
36.
go back to reference Weiser SD, Tsai AC, Gupta R, Frongillo EA, Kawuma A, Senkungu J, et al. Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. AIDS. 2012;26(1):67–75.CrossRefPubMedPubMedCentral Weiser SD, Tsai AC, Gupta R, Frongillo EA, Kawuma A, Senkungu J, et al. Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. AIDS. 2012;26(1):67–75.CrossRefPubMedPubMedCentral
37.
go back to reference Drain PK, Kupka R, Mugusi F, Fawzi WW. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr. 2007;85(2):333–45.PubMed Drain PK, Kupka R, Mugusi F, Fawzi WW. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr. 2007;85(2):333–45.PubMed
38.
go back to reference Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65.CrossRefPubMed Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65.CrossRefPubMed
39.
go back to reference Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PloS one. 2010;5(4):e10340.CrossRefPubMedPubMedCentral Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PloS one. 2010;5(4):e10340.CrossRefPubMedPubMedCentral
40.
go back to reference Nagata JM, Magerenge RO, Young SL, Oguta JO, Weiser SD, Cohen CR. Social determinants, lived experiences, and consequences of household food insecurity among persons living with HIV/AIDS on the shore of Lake Victoria, Kenya. AIDS Care. 2011;24(6):728–36. Nagata JM, Magerenge RO, Young SL, Oguta JO, Weiser SD, Cohen CR. Social determinants, lived experiences, and consequences of household food insecurity among persons living with HIV/AIDS on the shore of Lake Victoria, Kenya. AIDS Care. 2011;24(6):728–36.
41.
go back to reference UNHCR. Changing regional trends in HIV-related behaviours in refugee camps and surrounding communities. Geneva: UNHCR; 2011. UNHCR. Changing regional trends in HIV-related behaviours in refugee camps and surrounding communities. Geneva: UNHCR; 2011.
42.
go back to reference UNHCR. Behavioural surveillance surveys among refugees and surrounding host population (Kakuma, Kenya). Geneva: UNHCR; 2004. UNHCR. Behavioural surveillance surveys among refugees and surrounding host population (Kakuma, Kenya). Geneva: UNHCR; 2004.
43.
go back to reference Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54(11):1660–9.CrossRefPubMed Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54(11):1660–9.CrossRefPubMed
44.
go back to reference Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral
Metadata
Title
Low levels of viral suppression among refugees and host nationals accessing antiretroviral therapy in a Kenyan refugee camp
Authors
Joshua B. Mendelsohn
Paul Spiegel
Alison Grant
Sathyanarayanan Doraiswamy
Marian Schilperoord
Natasha Larke
John Wagacha Burton
Jully A. Okonji
Clement Zeh
Bosco Muhindo
Ibrahim M. Mohammed
Irene N. Mukui
Njogu Patterson
Egbert Sondorp
David A. Ross
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Conflict and Health / Issue 1/2017
Electronic ISSN: 1752-1505
DOI
https://doi.org/10.1186/s13031-017-0111-3

Other articles of this Issue 1/2017

Conflict and Health 1/2017 Go to the issue